Skip to main content
Clinical Trials/NL-OMON31361
NL-OMON31361
Not yet recruiting
Phase 3

Placebo controlled trial to evaluate the effect on pain and function of six months treatment doxycycline in established knee osteoarthritis with an open extension up to two years - Symptomatic treatment with doxycycline in established knee osteoarthritis

Sint Maartenskliniek0 sites230 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Sint Maartenskliniek
Enrollment
230
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • · Knee OA (index knee) according to the 1986 proposed ACR classification tree using clinical and radiological criteria: knee pain (VAS \> 40mm during \> 50% of last month), the presence of osteophytes and one of the following: age \>50, crepitus, or morning stiffness \< 30 minutes.
  • · Kellgren Lawrence score II or III
  • · Criteria for mild to severe pain (KOOS pain sumscore question 5 to 9 \> 100 in the index knee) must be fulfilled
  • · Ability to read and communicate well in Dutch.

Exclusion Criteria

  • · Other rheumatic diseases like rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematodes or psoriatic arthritis.
  • · The presence of secondary OA including OA caused by orthopaedic problems (severe malalignment, trauma), ochronosis, acromegaly, calcium pyrophosphate deposition disease (CPPD), haemochromatosis.
  • · Severe functional problems related to diseases other than OA (functional class ARA IV)
  • · Cognitive deficits affecting the scoring processes.
  • · Severe OA (Kellgren Lawrence score IV)
  • · Ipsilateral hip prosthesis in situ.
  • · Contraindications for doxycycline use like allergy for tetracyclines and prior adequate treatment with doxycycline (\>100mg for \> 6 weeks for OA).
  • · Planned other major interventions within 24 weeks, including lower limb surgery and intensive multidisciplinary approaches.
  • · Recent intra\-articular hyaluronic acid or corticosteroid application (\<3 months) or surgery (\<1 year) in the index knee.
  • · Recent participation in other study (\< 3 months)

Outcomes

Primary Outcomes

Not specified

Similar Trials